SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Paracelsian Inc (PRLN)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Jonathan Schonsheck who wrote (4243)5/25/1999 10:21:00 PM
From: Jonathan Schonsheck   of 4342
 
One point that I believe is underappreciated by the market - and perhaps some stockholders: the three main business "units" are independent. If the BioFIT Certification program is slowed by unforeseen events, that will have no impact on the marketing of the Ah-Immunoassay, or Drug Discovery. But if it rolls out as intended, the revenues can be used to enhance the other two programs (as well as BioFIT itself). If Kubota drags its feet, that doesn't slow BioFIT or Drug Discovery - but if it rolls out as intended, the revenues can be devoted to BioFIT and DD as well. A "home run" in DD can support the other two initiatives; the need for additional research in DD won't be a problem for Kubota, or for Scherer/BioFIT. The consequence: a Company with strength, as well as potential.

Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News